WO2022218384A1 - 抗cd47的单克隆抗体及其用途 - Google Patents
抗cd47的单克隆抗体及其用途 Download PDFInfo
- Publication number
- WO2022218384A1 WO2022218384A1 PCT/CN2022/086890 CN2022086890W WO2022218384A1 WO 2022218384 A1 WO2022218384 A1 WO 2022218384A1 CN 2022086890 W CN2022086890 W CN 2022086890W WO 2022218384 A1 WO2022218384 A1 WO 2022218384A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- variant
- antibody
- amino acid
- variable region
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 83
- 239000003814 drug Substances 0.000 claims abstract description 60
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 29
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 142
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 135
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 107
- 108090000623 proteins and genes Proteins 0.000 claims description 90
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 83
- 239000012634 fragment Substances 0.000 claims description 82
- 102000004169 proteins and genes Human genes 0.000 claims description 80
- 239000000427 antigen Substances 0.000 claims description 70
- 108091007433 antigens Proteins 0.000 claims description 69
- 102000036639 antigens Human genes 0.000 claims description 69
- 238000009739 binding Methods 0.000 claims description 57
- 230000027455 binding Effects 0.000 claims description 56
- 229940079593 drug Drugs 0.000 claims description 43
- 150000001413 amino acids Chemical class 0.000 claims description 39
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 34
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims description 34
- 230000035772 mutation Effects 0.000 claims description 30
- 102000044459 human CD47 Human genes 0.000 claims description 27
- 108060003951 Immunoglobulin Proteins 0.000 claims description 25
- 102000018358 immunoglobulin Human genes 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 23
- 238000006467 substitution reaction Methods 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 18
- 229960002756 azacitidine Drugs 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 238000012217 deletion Methods 0.000 claims description 18
- 230000037430 deletion Effects 0.000 claims description 18
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 17
- 238000002347 injection Methods 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 15
- 229960004641 rituximab Drugs 0.000 claims description 14
- -1 anthracyclines Substances 0.000 claims description 13
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 12
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 12
- 229960005395 cetuximab Drugs 0.000 claims description 12
- 238000003780 insertion Methods 0.000 claims description 11
- 230000037431 insertion Effects 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 229960003347 obinutuzumab Drugs 0.000 claims description 11
- 229960001592 paclitaxel Drugs 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 10
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 9
- 229940044683 chemotherapy drug Drugs 0.000 claims description 9
- 101000840257 Homo sapiens Immunoglobulin kappa constant Proteins 0.000 claims description 8
- 102100029572 Immunoglobulin kappa constant Human genes 0.000 claims description 8
- 229930012538 Paclitaxel Natural products 0.000 claims description 8
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 101000961149 Homo sapiens Immunoglobulin heavy constant gamma 4 Proteins 0.000 claims description 7
- 102100039347 Immunoglobulin heavy constant gamma 4 Human genes 0.000 claims description 7
- 108020001507 fusion proteins Proteins 0.000 claims description 7
- 102000037865 fusion proteins Human genes 0.000 claims description 7
- 238000010255 intramuscular injection Methods 0.000 claims description 7
- 239000007927 intramuscular injection Substances 0.000 claims description 7
- 238000010253 intravenous injection Methods 0.000 claims description 7
- 238000010254 subcutaneous injection Methods 0.000 claims description 7
- 239000007929 subcutaneous injection Substances 0.000 claims description 7
- 230000008685 targeting Effects 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims description 6
- 208000032612 Glial tumor Diseases 0.000 claims description 6
- 206010018338 Glioma Diseases 0.000 claims description 6
- 101710138871 Ig gamma-1 chain C region Proteins 0.000 claims description 6
- 102100039345 Immunoglobulin heavy constant gamma 1 Human genes 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 6
- 230000008878 coupling Effects 0.000 claims description 6
- 238000010168 coupling process Methods 0.000 claims description 6
- 238000005859 coupling reaction Methods 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 5
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 230000009870 specific binding Effects 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 4
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229960004562 carboplatin Drugs 0.000 claims description 4
- 190000008236 carboplatin Chemical compound 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 230000004001 molecular interaction Effects 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 206010014950 Eosinophilia Diseases 0.000 claims description 3
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 3
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 3
- 108010069236 Goserelin Proteins 0.000 claims description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 3
- 241001529936 Murinae Species 0.000 claims description 3
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 3
- 229950000242 ancitabine Drugs 0.000 claims description 3
- KZOWNALBTMILAP-JBMRGDGGSA-N ancitabine hydrochloride Chemical compound Cl.N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 KZOWNALBTMILAP-JBMRGDGGSA-N 0.000 claims description 3
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 229960000684 cytarabine Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229940088598 enzyme Drugs 0.000 claims description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 3
- 229960002949 fluorouracil Drugs 0.000 claims description 3
- 229960005277 gemcitabine Drugs 0.000 claims description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 3
- 229960002913 goserelin Drugs 0.000 claims description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 3
- 229960001756 oxaliplatin Drugs 0.000 claims description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000003207 proteasome inhibitor Substances 0.000 claims description 3
- 229960001603 tamoxifen Drugs 0.000 claims description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 3
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 2
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims description 2
- XJGXCBHXFWBOTN-UHFFFAOYSA-N 4-[[4-fluoro-3-[2-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[1,5-a]pyrazine-7-carbonyl]phenyl]methyl]-2h-phthalazin-1-one Chemical compound C1CN2N=C(C(F)(F)F)N=C2CN1C(=O)C1=CC(CC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F XJGXCBHXFWBOTN-UHFFFAOYSA-N 0.000 claims description 2
- 208000023761 AL amyloidosis Diseases 0.000 claims description 2
- 201000008217 Aggressive systemic mastocytosis Diseases 0.000 claims description 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 2
- 102000015790 Asparaginase Human genes 0.000 claims description 2
- 108010024976 Asparaginase Proteins 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 229940123014 DNA polymerase inhibitor Drugs 0.000 claims description 2
- 208000008334 Dermatofibrosarcoma Diseases 0.000 claims description 2
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 201000001342 Fallopian tube cancer Diseases 0.000 claims description 2
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 2
- 206010073073 Hepatobiliary cancer Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 2
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 208000032818 Microsatellite Instability Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims description 2
- 201000008736 Systemic mastocytosis Diseases 0.000 claims description 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 206010043515 Throat cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 229960003272 asparaginase Drugs 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims description 2
- 201000000053 blastoma Diseases 0.000 claims description 2
- 229960004117 capecitabine Drugs 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims description 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims description 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 201000008184 embryoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 201000007492 gastroesophageal junction adenocarcinoma Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940127121 immunoconjugate Drugs 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 208000006178 malignant mesothelioma Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000005282 malignant pleural mesothelioma Diseases 0.000 claims description 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims description 2
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 229960001786 megestrol Drugs 0.000 claims description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000033607 mismatch repair Effects 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 2
- 229950011068 niraparib Drugs 0.000 claims description 2
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 2
- 229960000572 olaparib Drugs 0.000 claims description 2
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims description 2
- 229960005079 pemetrexed Drugs 0.000 claims description 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 2
- 201000002628 peritoneum cancer Diseases 0.000 claims description 2
- 208000037244 polycythemia vera Diseases 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims description 2
- 229950004707 rucaparib Drugs 0.000 claims description 2
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 230000002381 testicular Effects 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 230000002327 eosinophilic effect Effects 0.000 claims 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 1
- 208000023747 urothelial carcinoma Diseases 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 55
- 239000002609 medium Substances 0.000 description 41
- 108090000765 processed proteins & peptides Proteins 0.000 description 41
- 239000000047 product Substances 0.000 description 39
- 235000001014 amino acid Nutrition 0.000 description 35
- 229920001184 polypeptide Polymers 0.000 description 35
- 102000004196 processed proteins & peptides Human genes 0.000 description 35
- 230000000694 effects Effects 0.000 description 33
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 30
- 229940024606 amino acid Drugs 0.000 description 30
- 239000012091 fetal bovine serum Substances 0.000 description 30
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 30
- 210000002540 macrophage Anatomy 0.000 description 29
- 206010057249 Phagocytosis Diseases 0.000 description 27
- 230000008782 phagocytosis Effects 0.000 description 27
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 25
- 229920009537 polybutylene succinate adipate Polymers 0.000 description 25
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 20
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 19
- 239000006228 supernatant Substances 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 16
- 210000004881 tumor cell Anatomy 0.000 description 16
- 210000002865 immune cell Anatomy 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 13
- 230000028993 immune response Effects 0.000 description 13
- 229940125001 cadonilimab Drugs 0.000 description 12
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 10
- 229960004857 mitomycin Drugs 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 102100032741 SET-binding protein Human genes 0.000 description 9
- 102000025171 antigen binding proteins Human genes 0.000 description 9
- 108091000831 antigen binding proteins Proteins 0.000 description 9
- 229960000074 biopharmaceutical Drugs 0.000 description 9
- 230000000242 pagocytic effect Effects 0.000 description 9
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 102100020873 Interleukin-2 Human genes 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 230000004913 activation Effects 0.000 description 6
- 238000010494 dissociation reaction Methods 0.000 description 6
- 230000005593 dissociations Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000013613 expression plasmid Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 229940063500 penpulimab Drugs 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- 208000011691 Burkitt lymphomas Diseases 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 230000002380 cytological effect Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 102100022297 Integrin alpha-X Human genes 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 229940125644 antibody drug Drugs 0.000 description 4
- 229960003852 atezolizumab Drugs 0.000 description 4
- 229940121420 cemiplimab Drugs 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000013401 experimental design Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000005931 immune cell recruitment Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 description 4
- 229960003301 nivolumab Drugs 0.000 description 4
- 229960002621 pembrolizumab Drugs 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229940121514 toripalimab Drugs 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 3
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 description 3
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 101710098610 Leukocyte surface antigen CD47 Proteins 0.000 description 3
- 239000012515 MabSelect SuRe Substances 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 108010046722 Thrombospondin 1 Proteins 0.000 description 3
- 102100036034 Thrombospondin-1 Human genes 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 229950002916 avelumab Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229950004272 brigatinib Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 229960002633 ramucirumab Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 102100029968 Calreticulin Human genes 0.000 description 2
- 108090000549 Calreticulin Proteins 0.000 description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 2
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 102100032999 Integrin beta-3 Human genes 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 229960002833 aflibercept Drugs 0.000 description 2
- 108010081667 aflibercept Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229930189065 blasticidin Natural products 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 229960001467 bortezomib Drugs 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229950007712 camrelizumab Drugs 0.000 description 2
- 229960002438 carfilzomib Drugs 0.000 description 2
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 2
- 108010021331 carfilzomib Proteins 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 229960002465 dabrafenib Drugs 0.000 description 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 2
- 229960002448 dasatinib Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 102000055229 human IL4 Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 229960001507 ibrutinib Drugs 0.000 description 2
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 2
- 229960003685 imatinib mesylate Drugs 0.000 description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 229960003648 ixazomib Drugs 0.000 description 2
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 229960004338 leuprorelin Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940125645 monoclonal antibody drug Drugs 0.000 description 2
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229960002183 ponatinib hydrochloride Drugs 0.000 description 2
- BWTNNZPNKQIADY-UHFFFAOYSA-N ponatinib hydrochloride Chemical compound Cl.C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 BWTNNZPNKQIADY-UHFFFAOYSA-N 0.000 description 2
- 229950004043 radotinib Drugs 0.000 description 2
- DUPWHXBITIZIKZ-UHFFFAOYSA-N radotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3N=CC=NC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 DUPWHXBITIZIKZ-UHFFFAOYSA-N 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 229940121497 sintilimab Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229950007123 tislelizumab Drugs 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 229950007217 tremelimumab Drugs 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000001875 tumorinhibitory effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- AVIWDYSJSPOOAR-LSDHHAIUSA-N (1S,3R)-3-acetamido-N-[5-chloro-4-(5,5-dimethyl-4,6-dihydropyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl]cyclohexane-1-carboxamide Chemical compound C(C)(=O)N[C@H]1C[C@H](CCC1)C(=O)NC1=NC=C(C(=C1)C1=C2N(N=C1)CC(C2)(C)C)Cl AVIWDYSJSPOOAR-LSDHHAIUSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DLPIYBKBHMZCJI-WBVHZDCISA-N (2r,3s)-3-[[6-[(4,6-dimethylpyridin-3-yl)methylamino]-9-propan-2-ylpurin-2-yl]amino]pentan-2-ol Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CC)[C@@H](C)O)=NC=1NCC1=CN=C(C)C=C1C DLPIYBKBHMZCJI-WBVHZDCISA-N 0.000 description 1
- BXTJCSYMGFJEID-XMTADJHZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-[3-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-met Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C(SC[C@H](N)C(O)=O)CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 BXTJCSYMGFJEID-XMTADJHZSA-N 0.000 description 1
- BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
- KSMZEXLVHXZPEF-UHFFFAOYSA-N 1-[[4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine Chemical group COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)C=CN=C2C=C1OCC1(N)CC1 KSMZEXLVHXZPEF-UHFFFAOYSA-N 0.000 description 1
- VFVAQKKPFOPZEA-UHFFFAOYSA-N 2,6-bis(2-aminopyrimidin-4-yl)pyridin-3-ol Chemical compound NC1=NC=CC(=N1)C1=NC(=CC=C1O)C1=NC(=NC=C1)N VFVAQKKPFOPZEA-UHFFFAOYSA-N 0.000 description 1
- MRPGRAKIAJJGMM-OCCSQVGLSA-N 2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2r,3s)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one Chemical compound OC[C@@H]1N(C)CC[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC(=CC=1)C(F)(F)F)Cl)=CC2=O MRPGRAKIAJJGMM-OCCSQVGLSA-N 0.000 description 1
- PDGKHKMBHVFCMG-UHFFFAOYSA-N 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyrazino[5,6]pyrrolo[1,2-d]pyrimidine-9,1'-cyclohexane]-6-one Chemical compound C1CN(C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C2N3C4(CCCCC4)CNC2=O)C3=N1 PDGKHKMBHVFCMG-UHFFFAOYSA-N 0.000 description 1
- NWYDRHSNEATNRI-SQQVDAMQSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid (16E)-14-methyl-20-oxa-5,7,14,27-tetrazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2(27),3,5,8,10,12(26),16,21,23-decaene Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.N=1C2=CC=NC=1NC(C=1)=CC=CC=1CN(C)C\C=C\CCOC1=CC=CC2=C1 NWYDRHSNEATNRI-SQQVDAMQSA-N 0.000 description 1
- KDYHYRKDQJLNGS-UHFFFAOYSA-N 3-(5-hydroxy-3-nitroso-1H-indol-2-yl)-5-nitro-1H-indol-2-ol Chemical compound Oc1[nH]c2ccc(cc2c1-c1[nH]c2ccc(O)cc2c1N=O)[N+]([O-])=O KDYHYRKDQJLNGS-UHFFFAOYSA-N 0.000 description 1
- OVPNQJVDAFNBDN-UHFFFAOYSA-N 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Chemical compound ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 OVPNQJVDAFNBDN-UHFFFAOYSA-N 0.000 description 1
- VTGGYCCJUPYZSX-UHFFFAOYSA-N 4-methyl-n-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide;hydrochloride Chemical compound Cl.C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 VTGGYCCJUPYZSX-UHFFFAOYSA-N 0.000 description 1
- QIEKHLDZKRQLLN-FOIQADDNSA-N 6-(difluoromethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound FC(C1=CC2=C(N=C(N=C2)NC2CCN(CC2)S(=O)(=O)C)N(C1=O)[C@H]1[C@](CCC1)(C)O)F QIEKHLDZKRQLLN-FOIQADDNSA-N 0.000 description 1
- SGJLSPUSUBJWHO-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperidin-4-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1C1CCNCC1 SGJLSPUSUBJWHO-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 229940124618 Anlotinib Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- PKUWDLWKNZVLHK-UHFFFAOYSA-N BPI Chemical compound BPI PKUWDLWKNZVLHK-UHFFFAOYSA-N 0.000 description 1
- 238000010152 Bonferroni least significant difference Methods 0.000 description 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100040500 Contactin-6 Human genes 0.000 description 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000749869 Homo sapiens Contactin-6 Proteins 0.000 description 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 1
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 229940125999 RMC-4550 Drugs 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010086229 SYN-004 Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 1
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- IKUYEYLZXGGCRD-ORAYPTAESA-N [3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl]methanol Chemical compound N[C@@H]1[C@@H](OCC11CCN(CC1)C=1C(=NC(=C(N=1)C)C1=C(C(=CC=C1)Cl)Cl)CO)C IKUYEYLZXGGCRD-ORAYPTAESA-N 0.000 description 1
- 229950001573 abemaciclib Drugs 0.000 description 1
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 description 1
- 229950009821 acalabrutinib Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 229960004416 alectinib hydrochloride Drugs 0.000 description 1
- GYABBVHSRIHYJR-UHFFFAOYSA-N alectinib hydrochloride Chemical compound Cl.CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 GYABBVHSRIHYJR-UHFFFAOYSA-N 0.000 description 1
- LGMSNQNWOCSPIK-LWHGMNCYSA-N alvocidib hydrochloride Chemical compound Cl.O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O LGMSNQNWOCSPIK-LWHGMNCYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 229940008421 amivantamab Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- 229960004152 bosutinib monohydrate Drugs 0.000 description 1
- NHANOMFABJQAAH-UHFFFAOYSA-N butanedioic acid;7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound OC(=O)CCC(O)=O.N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 NHANOMFABJQAAH-UHFFFAOYSA-N 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940011171 cinrebafusp alfa Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229950002756 depatuxizumab Drugs 0.000 description 1
- 229950008925 depatuxizumab mafodotin Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 229940121550 disitamab vedotin Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229940125017 ebvaciclib Drugs 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940013204 fadraciclib Drugs 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000003652 hormone inhibitor Substances 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229950005646 imgatuzumab Drugs 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940121577 lerociclib Drugs 0.000 description 1
- YPJRHEKCFKOVRT-UHFFFAOYSA-N lerociclib Chemical compound C1CN(C(C)C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C2N3C4(CCCCC4)CNC2=O)C3=N1 YPJRHEKCFKOVRT-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 229950003135 margetuximab Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229950009655 milciclib Drugs 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- RXZMYLDMFYNEIM-UHFFFAOYSA-N n,1,4,4-tetramethyl-8-[4-(4-methylpiperazin-1-yl)anilino]-5h-pyrazolo[4,3-h]quinazoline-3-carboxamide Chemical compound CNC(=O)C1=NN(C)C(C2=N3)=C1C(C)(C)CC2=CN=C3NC(C=C1)=CC=C1N1CCN(C)CC1 RXZMYLDMFYNEIM-UHFFFAOYSA-N 0.000 description 1
- VRKZHYSJZOUICG-UHFFFAOYSA-N n-(5-fluoro-2-piperidin-1-ylphenyl)pyridine-4-carbothioamide Chemical compound C=1C=NC=CC=1C(=S)NC1=CC(F)=CC=C1N1CCCCC1 VRKZHYSJZOUICG-UHFFFAOYSA-N 0.000 description 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- 229950002926 nepidermin Drugs 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229940030721 nilotinib hydrochloride Drugs 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical group N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229950010518 ribociclib succinate Drugs 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- 229960002539 ruxolitinib phosphate Drugs 0.000 description 1
- JFMWPOCYMYGEDM-XFULWGLBSA-N ruxolitinib phosphate Chemical compound OP(O)(O)=O.C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 JFMWPOCYMYGEDM-XFULWGLBSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229950000055 seliciclib Drugs 0.000 description 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229940060960 tomuzotuximab Drugs 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 229940049679 trastuzumab deruxtecan Drugs 0.000 description 1
- 229950009027 trastuzumab duocarmazine Drugs 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- 108010075758 trebananib Proteins 0.000 description 1
- 229950001210 trebananib Drugs 0.000 description 1
- 229950007127 trilaciclib Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 1
- 229960001183 venetoclax Drugs 0.000 description 1
- 229950003294 voruciclib Drugs 0.000 description 1
- 229940020820 zanidatamab Drugs 0.000 description 1
- 229950007155 zenocutuzumab Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (19)
- 药物组合物,优选用于治疗肿瘤,所述药物组合物包含组分A和组分B,其中所述组分A为特异性结合CD47的抗体或其抗原结合片段,其中组分B选自下述的一种或多种:组分B1,组分B2和组分B3,其中组分B1为双特异性抗体或其抗原结合片段,组分B2为肿瘤化疗药,组分B3为抗PD-1单克隆抗体或其抗原结合片段,优选地,组合物还包含组分C,组分C为肿瘤治疗剂,并且组分C不同于组分B,例如根据Kabat,IMGT,Chothia或AbM编号系统,所述特异性结合CD47的抗体包含选自以下重链可变区和轻链可变区中包含的CDR序列(1)SEQ ID NO:2所示的重链可变区包含的HCDR1,HCDR2和HCDR3,和SEQ ID NO:4所示的轻链可变区包含的LCDR1,LCDR2和LCDR3;或(2)SEQ ID NO:12所示的重链可变区包含的HCDR1,HCDR2和HCDR3,和SEQ ID NO:14所示的轻链可变区包含的LCDR1,LCDR2和LCDR3;或(3)SEQ ID NO:16所示的重链可变区包含的HCDR1,HCDR2和HCDR3,和SEQ ID NO:18所示的轻链可变区包含的LCDR1,LCDR2和LCDR3;或(4)SEQ ID NO:20所示的重链可变区包含的HCDR1,HCDR2和HCDR3,和SEQ ID NO:22所示的轻链可变区包含的LCDR1,LCDR2和LCDR3(优选地,根据IMGT编号系统,所述抗体包含:HCDR1,其包含SEQ ID NO:5所示的序列或其变体,或由其组成,HCDR2,其包含SEQ ID NO:6所示的序列或其变体,或由其组成,和HCDR3,其包含SEQ ID NO:7所示的序列或其变体,或由其组成,并且所述抗体还包含:LCDR1,其包含SEQ ID NO:8所示的氨基酸或其变体,或由其组成,LCDR2,其包含SEQ ID NO:9所示的氨基酸序列或其变体,或由其组成,和LCDR3,其包含SEQ ID NO:10所示的序列或其变体,或由其组成);其中所述双特异性抗体为抗PD-1-抗CTLA4抗体或抗PD-1-抗VEGFA抗体或二者的组合,所述双特异性抗体包含第一蛋白功能区和第二蛋白功能区,其中所述第一蛋白功能区靶向PD-1,所述第二蛋白功能区靶向CTLA4或VEGFA, 其中,所述第一蛋白功能区为免疫球蛋白,所述第二蛋白功能区为单链抗体;或者,所述第一蛋白功能区为单链抗体,所述第二蛋白功能区为免疫球蛋白;优选地,一个免疫球蛋白分子连接有两个单链抗体分子(优选地,两个单链抗体分子相同),优选地,所述免疫球蛋白为IgG1亚型(优选人IgG1亚型),优选地,所述单链抗体连接到所述免疫球蛋白重链的N端或C端,其中,所述第一蛋白功能区和第二蛋白功能区独立地为1个、2个或者2个以上,优选地,所述第一蛋白功能区与所述第二蛋白功能区直接连接或者通过第一连接片段连接;和/或所述单链抗体的重链可变区与所述单链抗体的轻链可变区直接连接或者通过第二连接片段连接,所述第一连接片段和所述第二连接片段相同或不同;优选地,所述连接片段为(GGGGS)n,n为正整数;更优选地,n为1、2、3、4、5或6;优选地,所述第一连接片段和所述第二连接片段的氨基酸序列独立地选自SEQ ID NO:119和SEQ ID NO:120;更优选地,所述第一连接片段和所述第二连接片段的氨基酸序列均如SEQ ID NO:120所示,其中当双特异性抗体为抗PD-1-抗CTLA4抗体时,所述第一蛋白功能区包含SEQ ID NO:87所示的重链可变区包含的HCDR1-HCDR3,和SEQ ID NO:88所示的轻链可变区包含的LCDR1-LCDR3(优选地,根据IMGT编号系统,所述第一蛋白功能区包含HCDR1,其包含SEQ ID NO:89所示的序列或其变体,或由其组成,HCDR2,其包含SEQ ID NO:90所示的序列或其变体,或由其组成,和HCDR3,其包含SEQ ID NO:91所示的序列或其变体,或由其组成,LCDR1,其包含SEQ ID NO:92所示的氨基酸或其变体,或由其组成,LCDR2,其包含SEQ ID NO:93所示的氨基酸序列或其变体,或由其组成,和LCDR3,其包含SEQ ID NO:94所示的序列或其变体,或由其组成);所述第二蛋白功能区包含SEQ ID NO:95所示的重链可变区中的HCDR1-HCDR3和SEQ ID NO:96所示的轻链可变区中的LCDR1-LCDR3(优选地,根据IMGT编号系统,所述第二蛋白功能区包含HCDR1,其包含SEQ ID NO:97所示的序列或其变体,或由其组成,HCDR2,其包含SEQ ID NO:98所示的序列或其变体,或由其组成,HCDR3,其包含SEQ ID NO:99所示的序列或其变体,或由其组成,LCDR1,其包含SEQ ID NO:100所示的氨基酸或其变体,或由其组成,LCDR2,其包含SEQ ID NO:101所示的氨基酸序列或其变体,或由其组成,和LCDR3,其包含SEQ ID NO:102所示的序列或其变体,或由其组成);或者其中当双特异性抗体为抗PD-1-抗VEGFA抗体时,所述第一蛋白功能区包含SEQ ID NO:103所示的重链可变区包含的 HCDR1-HCDR3,和SEQ ID NO:104所示的轻链可变区包含的LCDR1-LCDR3(优选地,根据IMGT编号系统,所述第一蛋白功能区包含HCDR1,其包含SEQ ID NO:105所示的序列或其变体,或由其组成,HCDR2,其包含SEQ ID NO:106所示的序列或其变体,或由其组成,和HCDR3,其包含SEQ ID NO:107所示的序列或其变体,或由其组成,LCDR1,其包含SEQ ID NO:108所示的氨基酸或其变体,或由其组成,LCDR2,其包含SEQ ID NO:109所示的氨基酸序列或其变体,或由其组成,和LCDR3,其包含SEQ ID NO:110所示的序列或其变体,或由其组成);所述第二蛋白功能区包含SEQ ID NO:111所示的重链可变区中的HCDR1-HCDR3和SEQ ID NO:112所示的轻链可变区中的LCDR1-LCDR3(优选地,根据IMGT编号系统,所述第二蛋白功能区包含HCDR1,其包含SEQ ID NO:113所示的序列或其变体,或由其组成,HCDR2,其包含SEQ ID NO:114所示的序列或其变体,或由其组成,HCDR3,其包含SEQ ID NO:115所示的序列或其变体,或由其组成,LCDR1,其包含SEQ ID NO:116所示的氨基酸或其变体,或由其组成,LCDR2,其包含SEQ ID NO:117所示的氨基酸序列或其变体,或由其组成,和LCDR3,其包含SEQ ID NO:118所示的序列或其变体,或由其组成);其中所述抗PD1单克隆抗体包含SEQ ID NO:121所示的重链可变区包含的HCDR1-HCDR3和SEQ ID NO:122所示的轻链可变区包含的LCDR1-LCDR3(优选地根据IMGT编号系统,所述抗PD1单克隆抗体包含HCDR1,其包含SEQ ID NO:123所示的序列或其变体,或由其组成,HCDR2,其包含SEQ ID NO:124所示的序列或其变体,或由其组成,HCDR3,其包含SEQ ID NO:125所示的序列或其变体,或由其组成,LCDR1,其包含SEQ ID NO:126所示的氨基酸或其变体,或由其组成,LCDR2,其包含SEQ ID NO:127所示的氨基酸序列或其变体,或由其组成,和LCDR3,其包含SEQ ID NO:128所示的序列或其变体,或由其组成);其中,所述变体的序列与对应序列具有至少80%,81%,82%,83%,84%,85%,86%,87%,88%,89%,90%,91%,92%,93%,94%,95%,96%,97%,98%,99%同源性,或所述变体的序列与对应序列相比具有一个或多个(优选1个、2个或3个)保守氨基酸突变(优选置换,插入或缺失)。
- 权利要求1所述的药物组合物,其中所述特异性结合CD47的抗体还包含选自以下组成的组的重链可变区的框架区FR和轻链可变区的框架区FR:(1)所述重链可变区的框架区FR包含FR-H1,FR-H2,FR-H3和FR-H4,其中FR-H1包含SEQ ID NO:23的氨基酸序列或其变体,或由其列组成;FR-H2 包含SEQ ID NO:24的氨基酸序列或其变体,或由其组成;FR-H3包含SEQ ID NO:25的氨基酸序列或其变体,或由其组成;FR-H4包含SEQ ID NO:26的氨基酸序列或其变体,或由其组成,所述轻链可变区的框架区FR包含FR-L1,FR-L2,FR-L3和FR-L4,其中FR-L1包含SEQ ID NO:27的氨基酸序列或其变体,或由其组成;FR-L2包含SEQ ID NO:28的氨基酸序列或其变体,或由其组成;FR-L3包含SEQ ID NO:29的氨基酸序列或其变体,或由其组成;FR-L4包含SEQ ID NO:30的氨基酸序列或其变体,或由其组成;(2)所述重链可变区的框架区FR包含FR-H1,FR-H2,FR-H3和FR-H4,其中FR-H1包含SEQ ID NO:31的氨基酸序列或其变体,或由其组成;FR-H2包含SEQ ID NO:32的氨基酸序列或其变体,或由其组成;FR-H3包含SEQ ID NO:33的氨基酸序列或其变体,或由其组成;FR-H4包含SEQ ID NO:34的氨基酸序列或其变体,或由其组成,所述轻链可变区的框架区FR包含FR-L1,FR-L2,FR-L3和FR-L4,其中FR-L1包含SEQ ID NO:35的氨基酸序列或其变体,或由其组成;FR-L2包含SEQ ID NO:36的氨基酸序列或其变体,或由其组成;FR-L3包含SEQ ID NO:37的氨基酸序列或其变体,或由其组成;FR-L4包含SEQ ID NO:38的氨基酸序列或其变体,或由其组成;(3)所述重链可变区的框架区FR包含FR-H1,FR-H2,FR-H3和FR-H4,其中FR-H1包含SEQ ID NO:39的氨基酸序列或其变体,或由其组成;FR-H2包含SEQ ID NO:40的氨基酸序列或其变体,或由其组成;FR-H3包含SEQ ID NO:41的氨基酸序列或其变体,或由其组成;FR-H4包含SEQ ID NO:42的氨基酸序列或其变体,或由其组成,所述轻链可变区的框架区FR包含FR-L1,FR-L2,FR-L3和FR-L4,其中FR-L1包含SEQ ID NO:43的氨基酸序列或其变体,或由其组成;FR-L2包含SEQ ID NO:44的氨基酸序列或其变体,或由其组成;FR-L3包含SEQ ID NO:45的氨基酸序列或其变体,或由其组成;FR-L4包含SEQ ID NO:46的氨基酸序列或其变体,或由其组成;(4)所述重链可变区的框架区FR包含FR-H1,FR-H2,FR-H3和FR-H4,其中FR-H1包含SEQ ID NO:47的氨基酸序列或其变体,或由其组成;FR-H2包含SEQ ID NO:48的氨基酸序列或其变体,或由其组成;FR-H3包含SEQ ID NO:49的氨基酸序列或其变体,或由其组成;FR-H4包含SEQ ID NO:50的氨基酸序列或其变体,或由其组成,所述轻链可变区的框架区FR包含FR-L1,FR-L2,FR-L3和FR-L4,其中FR-L1包含SEQ ID NO:51的氨基酸序列或其变体,或由其组成;FR-L2包含SEQ ID NO:52的氨基酸序列或其变体,或由其组成;FR-L3包含SEQ ID NO:53的氨基酸序列或其变体,或由其组成;FR-L4包含SEQ ID NO:54的氨基酸序列或其变体,或由其组成,其中所述变体的序列与对应序列具有至少80%,优选至少81%,82%,83%,84%,85%,86%,87%,88%,89%,90%,91%,92%,93%,94%,95%,96%,97%,98%或99%同源性,或与对应序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9或10个)保守氨基酸突变(优选置换,插入或缺失)。
- 权利要求1或2所述的药物组合物,其中所述特异性结合CD47的抗体包括:(1)重链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:2所示的氨基酸序列,或其变体,和轻链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:4所示的氨基酸序列,或其变体;(2)重链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:12所示的氨基酸序列,或其变体,和轻链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:14所示的氨基酸序列,或其变体;(3)重链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:16所示的氨基酸序列,或其变体,和轻链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:18所示的氨基酸序列,或其变体;(4)重链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:20所示的氨基酸序列,或其变体,和轻链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:22所示的氨基酸序列,或其变体,其中所述抗PD-1-抗CTLA4抗体的第一蛋白功能区包含:(1)重链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:87所示的序列,或其变体,轻链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:88所示的序列,或其变体;(2)重链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:129所示的序列,或其变体,轻链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:130所示的序列,或其变体;所述抗PD-1-抗CTLA4抗体的第二蛋白功能区包含:(1)重链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:95所示的序列,或其变体,轻链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:96所示的序列,或其变体;(2)重链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:133所示的序列,或其变体,轻链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:134所示的序列,或其变体;(3)重链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:135所示的序列,或其变体,轻链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:136所示的序列,或其变体;(4)重链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:137所示的序列,或其变体,轻链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:138所示的序列,或其变体;(5)重链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:131所示的序列,或其变体,轻链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:132所示的序列,或其变体;优选地,所述抗PD-1-抗CTLA4抗体的免疫球蛋白包含的重链氨基酸序列如SEQ ID NO:139所示,靶向PD-1;其中所述抗PD-1-抗VEGFA抗体的第一蛋白功能区包含:(1)重链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:103所示的序列,或其变体,轻链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:104所示的序列,或其变体;所述抗PD-1-抗VEGFA抗体的第二蛋白功能区包含:(1)重链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:111所示的序列(优选由SEQ ID NO:145所示的核苷酸序列编码),或其变体,轻链可变区,其包含下述序列或由下述序列组成:SEQ ID NO:112所示的序列(优选由SEQ ID NO:146所示的核苷酸序列编码),或其变体;优选地,所述抗PD-1-抗VEGFA抗体的免疫球蛋白包含的重链氨基酸序 列如SEQ ID NO:140所示,靶向VEGFA;其中所述抗PD-1单克隆抗体包含SEQ ID NO:121所示的重链可变区和SEQ ID NO:122所示的轻链可变区,或由其组成;其中所述变体与对应序列具有至少85%,优选86%,87%,88%,89%,90%,91%,92%,93%,94%,95%,96%,97%,98%或99%以上序列同一性,或与对应序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28、29或30个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列。
- 权利要求1-3任一项所述的药物组合物,其中所述特异性结合CD47的抗体还包含重链恒定区和轻链恒定区,且所述恒定区来自不是鼠类的物种,例如来自人抗体,优选来自人IgG或IgM,更优选IgG1,优选地,所述重链恒定区为Ig gamma-1 chain C region,ACCESSION:P01857(SEQ ID NO:58)或Ig gamma-4 chain C region,ACCESSION:P01861.1(SEQ ID NO:56);所述轻链恒定区为Ig kappa chain C region,ACCESSION:P01834(SEQ ID NO:57),优选地,所述特异性结合CD47抗体由保藏编号为CCTCC NO:2018135的杂交瘤细胞株LT012分泌。
- 权利要求1-4任一项所述的药物组合物,按照EU编号系统,所述特异性结合CD47的抗体和所述免疫球蛋白的重链恒定区在第234位点、235位点和237位点中的任意1个位点、2个位点或3个位点发生突变,并且突变后,双特异性抗体与FcγRIIIa和/或C1q的亲和力常数相比突变前降低;优选地,所述亲和力常数通过Fortebio Octet分子相互作用仪测得,优选地,所述特异性结合CD47的抗体按照EU编号系统包含突变L234A和/或L235A,更优选地,所述免疫球蛋白的重链恒定区具有如下突变组合之一:L234A和L235A;或者L234A和G237A;或者L235A和G237A;或者L234A、L235A、G237A,进一步优选地按照EU编号系统,所述免疫球蛋白的重链恒定区还具有如下突变组合之一:N297A、D265A、D270A、P238D、L328E、E233D、H268D、P271G、A330R、C226S、C229S、E233P、P331S、S267E、L328F、A330L、M252Y、S254T、T256E、N297Q、P238S、P238A、A327Q、A327G、P329A、K322A、T394D、G236R、G236A、L328R、A330S、P331S、H268A、E318A和K320A。
- 权利要求1-5任一项所述的药物组合物,其中所述特异性结合CD47的 抗体包含选自以下组成的组的重链和轻链,或由其组成:(1)SEQ ID NO:59表示的重链和SEQ ID NO:60表示的轻链;(2)SEQ ID NO:61表示的重链和SEQ ID NO:62表示的轻链;(3)SEQ ID NO:63表示的重链和SEQ ID NO:64表示的轻链;(4)SEQ ID NO:65表示的重链和SEQ ID NO:66表示的轻链;(5)SEQ ID NO:67表示的重链和SEQ ID NO:68表示的轻链;和(6)SEQ ID NO:69表示的重链和SEQ ID NO:70表示的轻链,所述抗PD-1-抗CTLA4抗体包含选自以下组成的重链和轻链,或由其组成:SEQ ID NO:78表示的重链(优选由SEQ ID NO:77所示的核苷酸序列编码)和SEQ ID NO:80表示的轻链(优选由SEQ ID NO:79所示的核苷酸序列编码);所述抗PD-1-抗VEGFA抗体包含选自以下组成的组的重链和轻链,或由其组成:SEQ ID NO:141表示的重链(优选由SEQ ID NO:142所示的核苷酸序列编码)和SEQ ID NO:143表示的轻链(优选由SEQ ID NO:144所示的核苷酸序列编码);所述抗PD-1单克隆抗体包含选自以下组成的组的重链和轻链,或由其组成:SEQ ID NO:82表示的重链(优选由SEQ ID NO:81所示的核苷酸序列编码),SEQ ID NO:84表示的轻链(优选由SEQ ID NO:83所示的核苷酸序列编码)。
- 权利要求1-6任一项所述的药物组合物,其中所述抗原结合片段选自Fab、Fab'、F(ab') 2、Fd、Fv、dAb、Fab/c、互补决定区(CDR)片段、单链抗体(例如,scFv)、双价抗体或结构域抗体。
- 权利要求1-7任一项所述的药物组合物,其中所述特异性结合CD47的抗体是人源化抗体、嵌合抗体、多特异性抗体(例如双特异性抗体)。
- 权利要求1-8任一项所述的药物组合物,其中所述特异性结合CD47的抗体以小于大约10 -5M,例如小于大约10 -6M、10 -7M、10 -8M、10 -9M或10 -10M或更小的KD结合人CD47蛋白,或者所述特异性结合CD47的抗体以小于大约100nM,例如小于大约10nM、1nM、0.9nM、0.8nM、0.7nM、0.6nM、0.5nM、0.4nM、0.3nM、0.2nM、0.1nM或更小的EC50结合人CD47蛋白。
- 权利要求1-9任一项所述的药物组合物,其中所述特异性结合CD47的抗体为抗体偶联物形式,其包括权利要求1-9任一项所述的特异性结合CD47的抗体或其抗原结合片段,以及与所述特异性结合CD47的抗体或其抗原结合片段偶联的偶联部分,所述偶联部分为纯化标签(如His标签)、细胞毒性剂,或可检测的标记。优选地,所述偶联部分为放射性同位素、发光物质、有色物质、酶或聚乙二醇,或者所述特异性结合CD47的抗体为多特异性抗体形式,优选双特异性抗体形 式,其包括权利要求1-9任一项所述的特异性结合CD47的抗体或其抗原结合片段,以及针对其他抗原和/或其他抗原表位的抗体或抗原结合片段,或者所述特异性结合CD47的抗体为融合蛋白形式,其包括权利要求1-9任一项所述的特异性结合CD47的抗体或其抗原结合片段。
- 权利要求1-10任一项所述的药物组合物,其中所述肿瘤治疗剂选自下述的一种或多种:酪氨酸激酶抑制剂、DNA多聚酶抑制剂、抗人CD20抗体、抗人PDL-1抗体、抗人PD-1抗体、抗人CTLA-4抗体、BCL-2的抑制剂、抗人EGFR抗体、抗人HER2抗体、抗人HER3抗体、阿卡替尼、细胞周期蛋白依赖性激酶抑制剂、抗人VEGFR2抗体、抗人VEGF抗体、蛋白酶体抑制剂、血管生成抑制剂、Rapidly accelerated fibrosarcoma(RAF)抑制剂、双特异性抗体和融合蛋白药物,优选地,所述治疗剂为Cetuximab,Obinutuzumab或Rituximab,优选地,肿瘤化疗药选自下述的一种或多种:烷化剂,蒽环类药物,抗代谢药物,抗生素,植物类药物和/或激素类药物,铂类药物(如顺铂、卡铂、奥沙利铂),阿霉素类,环磷酰胺,紫杉醇(如白蛋白紫杉醇,脂质体紫杉醇,多烯紫杉醇),依托泊苷,吉西他滨,培美曲塞,卡培他滨,奥拉帕利、芦卡帕利、尼拉帕利、他拉唑帕利、氟唑帕利,长春碱类,他莫昔芬,甲地孕酮,戈舍瑞林,门冬酰胺酶、氟尿嘧啶类抗肿瘤药(如5氟尿嘧啶)和阿扎胞苷、阿糖胞苷、环胞苷。
- 权利要求1-11任一项所述的药物组合物,其中所述药物组合物还包括药学上可接受的载体和/或赋形剂。
- 权利要求1-12任一项所述的药物组合物,其中按照抗体的质量计算,所述组分A与组分B1的质量比为(1:5)-(5:1),例如:1:5、1:4、1:3、1:2、1:1、2:1、3:1、4:1或5:1,所述组分A与组分B3的质量比为(1:5)-(5:1),例如:1:5、1:4、1:3、1:2、1:1、2:1、3:1、4:1或5:1,或者所述组分B2与组分A的质量比为1:(1-1000),优选为1:(5-500),更优选为1:(10-100),优选地,所述药物组合物中的组分A和组分B为适于为静脉滴注、皮下注射、皮内注射、静脉内注射、肌内注射或病灶内注射施用的形式。
- 试剂盒,优选用于治疗肿瘤,所述试剂盒包括A产品和产品B,其中所述产品A包含权利要求1-13任一项中所定义的所述特异性结合CD47的抗体或其抗原结合片段,产品B选自下述的一种或多种:产品B1,产品B2和产品B3,其中产品B1为权利要求1-13任一项中定义的所述双特异性抗体或其抗原结合片段(优选 地,当所述双特异性抗体为抗PD-1-抗CTLA4抗体和抗PD-1-抗VEGFA抗体组合时,所述抗PD-1-抗CTLA4抗体和抗PD-1-抗VEGFA抗体分别以独立包装存在或存在于同一个包装),产品B2为权利要求1-13任一项中定义的所述肿瘤化疗药,产品B3权利要求1-13任一项中定义的所述抗PD-1单克隆抗体或其抗原结合片段,其中产品B1、产品B2和产品B3分别以独立包装存在或存在于同一个包装,优选地,所述试剂盒还包含产品C,所述产品C为权利要求1-13任一项中定义的肿瘤治疗剂,并且所述产品C不同于所述产品B,优选地,所述试剂盒还包含产品说明书。
- 权利要求14所述的试剂盒,其中按照抗体的质量计算,所述产品A与产品B1的质量比为(1:5)-(5:1),例如:1:5、1:4、1:3、1:2、1:1、2:1、3:1、4:1或5:1,所述产品A与产品B3的质量比为(1:5)-(5:1),例如:1:5、1:4、1:3、1:2、1:1、2:1、3:1、4:1或5:1,或者肿瘤化疗药的单位剂量为0.1mg-100mg、0.5mg-50mg、1mg-20mg、2mg-15mg、4mg-12mg或者8mg-12mg,优选地,所述试剂盒中的产品A、产品B或产品C为适合静脉滴注、皮下注射、皮内注射、静脉内注射、肌内注射或病灶内注射施用的形式。
- 治疗或预防肿瘤的方法,包括给予有需求的受试者以有效量的权利要求1-13任一项中定义的组分A和组分B,优选地,所述方法还包括给予有需求的受试者以有效量的权利要求1-13任一项中定义的组分C,优选地,所述组分A、组分B和组分C同时或顺序施用;更优选地,所述组分A、组分B和组分C为在手术治疗之前或之后,和/或在放射治疗之前或之后施用;优选地,当组分B为组分B1和/或组分B3时,所述组分A或组分B的单次给药剂量为受试者的每千克体重0.1-100mg,优选1-10mg;或者所述组分A或组分B的单次给药剂量为每位受试者10-1000mg,优选50-500mg、100-400mg、150-300mg、150-250mg或200mg,优选地,组分B2的单位剂量为0.1mg-100mg、0.5mg-50mg、1mg-20mg、2mg-15mg、4mg-12mg或者8mg-12mg,优选地,每天两次至约每隔一天一次给药,或每3天、4天、5天、6天、10天、1周、2周、3周、4周、5周或6周给药一次;优选地,给药方式为静脉滴注、皮下注射、皮内注射、静脉内注射、肌内注射或病灶内注射施用的形式。
- 权利要求1-13任一项所述的药物组合物,权利要求14或15所述的试剂盒或权利要求16所述的方法,其中所述肿瘤优选为表达CD47的肿瘤,优选癌症,所述癌症包括实体瘤,血液瘤,淋巴瘤,母细胞瘤,肉瘤,白血病或淋巴样恶性肿瘤,更优选包括鳞状细胞癌,骨髓瘤,肺癌,小细胞肺癌,非小细胞肺癌,头颈鳞状细胞癌,胶质瘤(如神经胶质瘤、复发性胶质瘤),急性髓系白血病,霍奇金淋巴瘤,非霍奇金淋巴瘤,弥漫性大B细胞淋巴瘤,滤泡性淋巴瘤,急性淋巴细胞白血病,急性粒细胞性白血病,慢性淋巴细胞性白血病,慢性粒细胞性白血病,原发性纵向分离大B细胞淋巴瘤,套管细胞淋巴瘤,小淋巴细胞淋巴瘤,富含T细胞/组织细胞的大B细胞淋巴瘤,多发性骨髓瘤,髓样白血病-1蛋白,复发难治性的外周T细胞淋巴瘤,骨髓增生异常综合症,间变性大细胞淋巴瘤,套细胞淋巴瘤,边缘区淋巴瘤,骨髓纤维化,真性红细胞增多症、骨髓癌、骨髓及外骨髓增殖,侵袭性系统性肥大细胞增多症、嗜酸性粒细胞增多症、隆凸性皮肤纤维肉瘤,慢性嗜酸性白血病,胃肠道癌,胃癌或胃-食管结合部腺癌,卵巢癌,肝癌,淋巴细胞性白血病,大肠癌,子宫内膜癌,前列腺癌,甲状腺癌,黑色素瘤,软骨肉瘤,神经母细胞瘤,腺癌,胰腺癌,胰腺导管腺癌,多形性胶质母细胞瘤,骨癌,尤因氏肉瘤,宫颈癌,鼻咽癌,脑癌,膀胱癌,乳腺癌,三阴性乳腺癌,肠癌,直肠癌,结肠直肠癌,结肠癌,肝细胞癌,肾细胞癌,透明细胞肾细胞癌,头颈癌,咽喉癌,肝胆癌,中枢神经系统癌,食道癌,食管鳞癌,恶性胸膜间皮瘤,全身性轻链淀粉样变,淋巴细胞性淋巴瘤,骨髓增生性肿瘤,神经内分泌肿瘤,默克尔细胞癌,睾丸癌和皮肤癌,腹膜癌、输卵管癌,尿路上皮癌,微卫星高度不稳定性(MSI-H)或错配修复缺陷(dMMR)癌,间皮瘤。
- 单位制剂,优选用于治疗肿瘤,其中,所述单位制剂包含:1~10000mg(优选10-1000mg,优选50-500mg、100-400mg、150-300mg、150-250mg或200mg)的权利要求1-13任一项中定义的组分A和组分B,当组分B为组分B1和/或组分B3时,所述单位制剂包含1~10000mg(优选1-1000mg,优选50-500mg、100-400mg、150-300mg、150-250mg、200mg或100mg)的权利要求1-13任一项中定义的组分B,当组分B为组分B2时,所述单位制剂包含0.1mg-100mg、0.5mg-50mg、1mg-20mg、2mg-15mg、4mg-12mg或者8mg-12mg的组分B;优选地,所述单位制剂还包含一种或多种权利要求1-13任一项中定义的组分C;其中,所述组分A、组分B和组分C分别单独包装。
- 单次药物剂量单元,优选用于治疗肿瘤,其包含0.1-10000mg(优选1-1000mg,优选50-500mg、100-400mg、150-300mg、150-250mg、200mg或 100mg)的权利要求1-13任一项中定义的组分A,和组分B,当组分B为组分B1和/或组分B3时,所述单次药物剂量单元包含0.1-10000mg(优选1-1000mg,优选50-500mg、100-400mg、150-300mg、150-250mg、200mg或100mg)的权利要求1-13任一项中定义的组分B,当组分B为组分B2时,所述单次药物剂量单元包含0.1mg-100mg、0.5mg-50mg、1mg-20mg、2mg-15mg、4mg-12mg或者8mg-12mg的组分B。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22787606.7A EP4190816A1 (en) | 2021-04-14 | 2022-04-14 | Anti-cd47 monoclonal antibody and use thereof |
JP2023514956A JP2024515396A (ja) | 2021-04-14 | 2022-04-14 | 抗cd47モノクローナル抗体及びその使用 |
CA3193664A CA3193664A1 (en) | 2021-04-14 | 2022-04-14 | Anti-cd47 monoclonal antibody and use thereof |
IL305363A IL305363A (en) | 2021-04-14 | 2022-04-14 | Anti-CD47 monoclonal antibody and use thereof |
BR112023018450A BR112023018450A2 (pt) | 2021-04-14 | 2022-04-14 | Anticorpo monoclonal anti-cd47 e seu uso |
US18/024,471 US20240043531A1 (en) | 2021-04-14 | 2022-04-14 | Anti-cd47 monoclonal antibody and use thereof |
AU2022258273A AU2022258273A1 (en) | 2021-04-14 | 2022-04-14 | Anti-cd47 monoclonal antibody and use thereof |
KR1020237031123A KR20230170648A (ko) | 2021-04-14 | 2022-04-14 | 항-cd47 단일클론 항체 및 이의 용도 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110404033 | 2021-04-14 | ||
CN202110404033.2 | 2021-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022218384A1 true WO2022218384A1 (zh) | 2022-10-20 |
Family
ID=83575257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/086890 WO2022218384A1 (zh) | 2021-04-14 | 2022-04-14 | 抗cd47的单克隆抗体及其用途 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20240043531A1 (zh) |
EP (1) | EP4190816A1 (zh) |
JP (1) | JP2024515396A (zh) |
KR (1) | KR20230170648A (zh) |
CN (1) | CN115192718A (zh) |
AU (1) | AU2022258273A1 (zh) |
BR (1) | BR112023018450A2 (zh) |
CA (1) | CA3193664A1 (zh) |
IL (1) | IL305363A (zh) |
WO (1) | WO2022218384A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109053895B (zh) * | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
WO2021004480A1 (zh) * | 2019-07-08 | 2021-01-14 | 南京金斯瑞生物科技有限公司 | 抗cd47/抗pd-1双特异抗体及其制备方法和应用 |
CN112300286A (zh) * | 2019-08-02 | 2021-02-02 | 康方药业有限公司 | 抗ctla4-抗pd-1双特异性抗体及其用途 |
CN112442123A (zh) * | 2019-09-03 | 2021-03-05 | 中山康方生物医药有限公司 | 抗cd47的单克隆抗体及其用途 |
CN112830972A (zh) * | 2019-11-25 | 2021-05-25 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双特异性抗体、其药物组合物及其用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020324185A1 (en) * | 2019-08-02 | 2022-03-03 | CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. | Anti-PD-1 antibody and medical use thereof |
-
2022
- 2022-04-14 KR KR1020237031123A patent/KR20230170648A/ko unknown
- 2022-04-14 CN CN202210394792.XA patent/CN115192718A/zh active Pending
- 2022-04-14 CA CA3193664A patent/CA3193664A1/en active Pending
- 2022-04-14 JP JP2023514956A patent/JP2024515396A/ja active Pending
- 2022-04-14 WO PCT/CN2022/086890 patent/WO2022218384A1/zh active Application Filing
- 2022-04-14 AU AU2022258273A patent/AU2022258273A1/en active Pending
- 2022-04-14 EP EP22787606.7A patent/EP4190816A1/en active Pending
- 2022-04-14 US US18/024,471 patent/US20240043531A1/en active Pending
- 2022-04-14 BR BR112023018450A patent/BR112023018450A2/pt unknown
- 2022-04-14 IL IL305363A patent/IL305363A/en unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
WO2021004480A1 (zh) * | 2019-07-08 | 2021-01-14 | 南京金斯瑞生物科技有限公司 | 抗cd47/抗pd-1双特异抗体及其制备方法和应用 |
CN112300286A (zh) * | 2019-08-02 | 2021-02-02 | 康方药业有限公司 | 抗ctla4-抗pd-1双特异性抗体及其用途 |
CN112442123A (zh) * | 2019-09-03 | 2021-03-05 | 中山康方生物医药有限公司 | 抗cd47的单克隆抗体及其用途 |
CN112830972A (zh) * | 2019-11-25 | 2021-05-25 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双特异性抗体、其药物组合物及其用途 |
Non-Patent Citations (41)
Title |
---|
"GenBank", Database accession no. NP-542970.1 |
"Molecular Cloning: A Laboratory Manual" |
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY |
ACIERNO ET AL.: "Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibodies", J MOL BIOL., vol. 374, no. 1, 2007, pages 130 - 46, XP022310713, DOI: 10.1016/j.jmb.2007.09.005 |
AL TSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 402 |
ALTSCHUL ET AL., MOL. BIOL., vol. 215, 1990, pages 403 - 410 |
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426 |
CLARK, IMMUNOL. TODAY, vol. 21, 2000, pages 397 - 402 |
FENG, DONGDONG ET AL.: "Combination treatment with 5F9 and azacitidine enhances phagocytic elimination of acute myeloid leukemia", BLOOD, vol. 132, no. supplement 1, 29 November 2018 (2018-11-29), XP086590116, DOI: 10.1182/blood-2018-99-120170 * |
GONNET ET AL., SCIENCE, vol. 256, 1992, pages 1443 - 45 |
HAGE TREINEMER PSEBALD W.: "Crystals of a 1:1 Complex Between Human Interleukin-4 and the Extracellular Domain of Its Receptor Alpha Chain", EUR. J. BIOCHEM., vol. 258, no. 2, 1998, pages 831 - 6, XP003018346, DOI: 10.1046/j.1432-1327.1998.2580831.x |
HUA TAO, QIAN PUDONG, WANG FEIJIANG, YU HONGLIANG, GUO YESONG: "Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model", ONCOLOGY RESEARCH., PERGAMON PRESS, NEW YORK, NY., US, vol. 25, no. 9, 2 November 2017 (2017-11-02), US , pages 1579 - 1587, XP055540506, ISSN: 0965-0407, DOI: 10.3727/096504017X14900505020895 * |
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA., vol. 90, 1988, pages 5879 - 5883 |
JAISWAL SJAMIESON C H MPANG W W ET AL., CELL, vol. 138, no. 3, 2009, pages 271 - 285 |
JIANG PLAGENAUR CFNARAYANAN V: "Integrin-associated Protein Is a Ligand for the P84 Neural Adhesion Molecule", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, 1999, pages 559 - 62 |
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525 |
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 |
KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553 |
LIAN SHU, XIE RUIZHI, YE YUYING, LU YUSHENG, CHENG YUNLONG, XIE XIAODONG, LI SHUHUI, JIA LEE: "Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells", SCIENTIFIC REPORTS, NATURE PUBLISHING GROUP, vol. 9, no. 1, 14 December 2019 (2019-12-14), XP055884207, DOI: 10.1038/s41598-019-40241-1 * |
LIU JIANJUN, CHINESE JOURNAL OF CELLULAR AND MOLECULAR IMMUNOLOGY, vol. 1989, no. 4, pages 29 - 29 |
MATOZAKI TMURATA YOKAZAWA H ET AL.: "Functions and molecular mechanisms of the CD47-SIRPa signaling pathway", TRENDS IN CELL BIOLOGY, vol. 19, no. 2, 2009, pages 72 - 80 |
OLDENBORG P AZHELEZNYAK AFANG Y F ET AL.: "Role of CD47 as a marker of self on red blood cells", SCIENCE, vol. 288, no. 5473, 2000, pages 2051 - 2054, XP055304810, DOI: 10.1126/science.288.5473.2051 |
PEARSON, METHODS ENZYMOL., vol. 183, 1990, pages 63 - 98 |
PEARSON, METHODS MOL. BIOL., vol. 132, 2000, pages 185 - 219 |
PEARSON, METHODS MOL. BIOL., vol. 243, 1994, pages 307 - 31 |
PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596 |
RAJAGOPAL ET AL., PROT. ENGIN., vol. 10, 1997, pages 1453 - 1459 |
REICHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329 |
REITER ET AL., CANCER RES., vol. 54, 1994, pages 2714 - 2718 |
REITER ET AL., IMMUNITY, vol. 2, 1995, pages 281 - 287 |
REITER ET AL., INTER J. OF CANCER, vol. 58, 1994, pages 142 - 149 |
REITER ET AL., JBC, vol. 269, 1994, pages 18327 - 18331 |
REITER ET AL., NAT. BIOTECHNOL., vol. 14, 1996, pages 1239 - 1245 |
REITER ET AL., PROTEIN ENGINEERING, vol. 8, 1995, pages 1323 - 1331 |
SONGSIVILAILACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321 |
VONDERHEIDE R H, NATURE MEDICINE, vol. 21, no. 10, 2015, pages 1122 |
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546 |
WATERSONE HANXBIO PTY LTD: "NCT04097769 The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies", CLINICALTRIALS, 23 September 2019 (2019-09-23), XP009540398 * |
WEBBER ET AL., MOLECULAR IMMUNOLOGY, vol. 32, 1995, pages 249 - 258 |
WHO DRUG INFORMATION, vol. 34, no. 2, 2020, pages 375 - 376 |
ZHAO LEI, LINGLING LI, SHIXUE CHEN, YI HU: "Computational design of novel tetra-specific antibody (PD-1/CD47/VEGF/TGF-ß) with IgG-like architecture against non-small cell lung cancer (NSCLC). | Journal of Clinical Oncology", JOURNAL OF CLINICAL ONCOLOGY, pages 1 - 4, XP055906329, Retrieved from the Internet <URL:https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.e14002> [retrieved on 20220329] * |
Also Published As
Publication number | Publication date |
---|---|
CA3193664A1 (en) | 2022-10-20 |
AU2022258273A1 (en) | 2023-09-14 |
CN115192718A (zh) | 2022-10-18 |
JP2024515396A (ja) | 2024-04-10 |
BR112023018450A2 (pt) | 2023-11-07 |
US20240043531A1 (en) | 2024-02-08 |
IL305363A (en) | 2023-10-01 |
EP4190816A1 (en) | 2023-06-07 |
KR20230170648A (ko) | 2023-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021202966B2 (en) | Humanized, mouse or chimeric anti-CD47 monoclonal antibodies | |
US20230192847A1 (en) | Tigit antibodies, encoding nucleic acids and methods of using said antibodies in vivo | |
IL254223B1 (en) | CD20 binding compounds and their uses | |
WO2021104302A1 (zh) | 抗pd-1-抗vegfa的双特异性抗体、其药物组合物及其用途 | |
CA3149853A1 (en) | Treatment and prevention of cancer using her3 antigen-binding molecules | |
CN114507285A (zh) | Vista抗原结合分子 | |
KR20210143192A (ko) | 변형된 Fc 단편, 이를 포함하는 항체 및 이의 응용 | |
JP2017507953A (ja) | 抗cd38抗体との併用療法 | |
AU2018366650A1 (en) | Single-domain antibodies and variants thereof against PD-L1 | |
JP2022545585A (ja) | 新規の抗cd39抗体 | |
KR20200139725A (ko) | Her3 항원 결합 분자 | |
KR20210093270A (ko) | 인간화 항-SIRPα 항체 | |
WO2022042719A1 (zh) | 抗vegf-抗pd-l1双特异性抗体、其药物组合物及用途 | |
WO2023151693A1 (zh) | 包含抗tigit抗体和抗pd-1-抗vegfa双特异性抗体的药物组合物及用途 | |
WO2021043220A1 (zh) | 抗cd47的单克隆抗体及其用途 | |
JP2023541473A (ja) | 抗4-1bb-抗pd-l1二重特異性抗体、ならびにその医薬組成物および使用 | |
WO2022218384A1 (zh) | 抗cd47的单克隆抗体及其用途 | |
WO2022188832A1 (zh) | 含有抗pd-1-抗vegfa双特异性抗体的药物组合及其用途 | |
WO2022095970A1 (zh) | 双特异抗体及其应用 | |
JP2023524102A (ja) | Abcb5に特異的な抗体およびその使用 | |
WO2023246247A1 (zh) | 药物组合物及其用途 | |
TW202313699A (zh) | 新型抗sirpa抗體 | |
CA3196930A1 (en) | Novel anti-claudin18 antibodies | |
KR20240038043A (ko) | 약학적 조성물 및 용도 | |
EA040870B1 (ru) | Варианты комбинированной терапии с антителами анти-cd38 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22787606 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3193664 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023514956 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2022787606 Country of ref document: EP Effective date: 20230303 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 305363 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022258273 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 803409 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2023/010687 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2022258273 Country of ref document: AU Date of ref document: 20220414 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023018450 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11202306399P Country of ref document: SG |
|
ENP | Entry into the national phase |
Ref document number: 112023018450 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230912 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |